Registry-based analysis of Icatibant and C1-inhibitor use in
treatment of laryngeal attacks of hereditary angioedema

J 2022

Registry-based analysis of Icatibant and C1-inhibitor use in treatment of laryngeal attacks of hereditary angioedema

HAKL, Roman, Pavel KUKLÍNEK, Marta SOBOTKOVA, Irena KRCMOVA, Pavlina KRALICKOVA et. al.

Basic information

Original name

Registry-based analysis of Icatibant and C1-inhibitor use in treatment of laryngeal attacks of hereditary angioedema

Authors

HAKL, Roman (203 Czech Republic, belonging to the institution), Pavel KUKLÍNEK (203 Czech Republic), Marta SOBOTKOVA (203 Czech Republic), Irena KRCMOVA (203 Czech Republic), Pavlina KRALICKOVA (203 Czech Republic), Martina VACHOVA (203 Czech Republic), Jana HANZLIKOVA (203 Czech Republic), Martina NOVACKOVA (203 Czech Republic), Michal SVOBODA (203 Czech Republic), Ingrid KOVÁČOVÁ (703 Slovakia) and Jiří LITZMAN (203 Czech Republic, guarantor, belonging to the institution)

Edition

CLINICAL AND EXPERIMENTAL ALLERGY, HOBOKEN, WILEY, 2022, 0954-7894

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30102 Immunology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 6.100

RIV identification code

RIV/00216224:14110/22:00126581

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1111/cea.14182

UT WoS

000810252200001

Keywords in English

Icatibant; C1-inhibitor; hereditary angioedema; laryngeal attacks

Abstract

V originále

Hereditary angioedema (HAE) is a rare condition which manifests as repeated episodes of localized subcutaneous or submucosal oedema. Oedemas involving the upper airways carry the risk of asphyxiation and death. The aim of this study was to present our clinical experience of icatibant and C1 inhibitor use for treating HAE-1/2 laryngeal attacks (LA). To our knowledge, this is the first direct comparison of these treatment approaches for LA.

Citovat

HAKL, Roman, Pavel KUKLÍNEK, Marta SOBOTKOVA, Irena KRCMOVA, Pavlina KRALICKOVA, Martina VACHOVA, Jana HANZLIKOVA, Martina NOVACKOVA, Michal SVOBODA, Ingrid KOVÁČOVÁ and Jiří LITZMAN. Registry-based analysis of Icatibant and C1-inhibitor use in treatment of laryngeal attacks of hereditary angioedema. CLINICAL AND EXPERIMENTAL ALLERGY. HOBOKEN: WILEY, 2022, vol. 52, No 8, p. 994-997. ISSN 0954-7894. Available from: https://dx.doi.org/10.1111/cea.14182.

@article{2215440,
   author = {Hakl, Roman and Kuklínek, Pavel and Sobotkova, Marta and Krcmova, Irena and Kralickova, Pavlina and Vachova, Martina and Hanzlikova, Jana and Novackova, Martina and Svoboda, Michal and Kováčová, Ingrid and Litzman, Jiří},
   article_location = {HOBOKEN},
   article_number = {8},
   doi = {http://dx.doi.org/10.1111/cea.14182},
   keywords = {Icatibant; C1-inhibitor; hereditary angioedema; laryngeal attacks},
   language = {eng},
   issn = {0954-7894},
   journal = {CLINICAL AND EXPERIMENTAL ALLERGY},
   title = {Registry-based analysis of Icatibant and C1-inhibitor use in treatment of laryngeal attacks of hereditary angioedema},
   url = {https://onlinelibrary.wiley.com/doi/10.1111/cea.14182},
   volume = {52},
   year = {2022}
}

TY  - JOUR
ID  - 2215440
AU  - Hakl, Roman - Kuklínek, Pavel - Sobotkova, Marta - Krcmova, Irena - Kralickova, Pavlina - Vachova, Martina - Hanzlikova, Jana - Novackova, Martina - Svoboda, Michal - Kováčová, Ingrid - Litzman, Jiří
PY  - 2022
TI  - Registry-based analysis of Icatibant and C1-inhibitor use in treatment of laryngeal attacks of hereditary angioedema
JF  - CLINICAL AND EXPERIMENTAL ALLERGY
VL  - 52
IS  - 8
SP  - 994-997
EP  - 994-997
PB  - WILEY
SN  - 09547894
KW  - Icatibant
KW  - C1-inhibitor
KW  - hereditary angioedema
KW  - laryngeal attacks
UR  - https://onlinelibrary.wiley.com/doi/10.1111/cea.14182
N2  - Hereditary angioedema (HAE) is a rare condition which manifests as repeated episodes of localized subcutaneous or submucosal oedema. Oedemas involving the upper airways carry the risk of asphyxiation and death. The aim of this study was to present our clinical experience of icatibant and C1 inhibitor use for treating HAE-1/2 laryngeal attacks (LA). To our knowledge, this is the first direct comparison of these treatment approaches for LA.
ER  -

HAKL, Roman, Pavel KUKLÍNEK, Marta SOBOTKOVA, Irena KRCMOVA, Pavlina KRALICKOVA, Martina VACHOVA, Jana HANZLIKOVA, Martina NOVACKOVA, Michal SVOBODA, Ingrid KOVÁČOVÁ and Jiří LITZMAN. Registry-based analysis of Icatibant and C1-inhibitor use in treatment of laryngeal attacks of hereditary angioedema. \textit{CLINICAL AND EXPERIMENTAL ALLERGY}. HOBOKEN: WILEY, 2022, vol.~52, No~8, p.~994-997. ISSN~0954-7894. Available from: https://dx.doi.org/10.1111/cea.14182.

Detailed Information on Publication Record